Can phenotypic pathway signatures improve the prediction of response to PI3K pathway inhibitors?

Although many inhibitors of the PI3K signaling pathway are currently undergoing clinical development, knowledge of the molecular determinants of response to these inhibitors is incomplete. Genetic changes in the tumor genome lead to alterations in drug sensitivity. However, the predictive value of these measures to identify responders is imperfect. Phenotypic gene expression signatures, which capture comprehensive biology of tumor cells and their microenvironment, may provide a more precise prediction of therapeutic response.

Section editor:Robert Copeland – Epizyme Inc., Cambridge, MA 02139, USA